Adverse drug reactions (ADRs) are one of the leading causes of morbidity and mortality in 2 health care. Understanding which drug targets are linked to ADRs can lead to the development 3 of safer medicines. Here, we analyze in vitro secondary pharmacology of common (off) targets 4 for 2134 marketed drugs. To associate these drugs with human ADRs, we utilized FDA Adverse 5 Event Reports and developed random forest models that predict ADR occurrences from in vitro 6 pharmacological profiles. By evaluating Gini importance scores of model features, we identify 7 221 target-ADR associations. Among these are established relations, such as the association of 8 in vitro hERG binding with cardiac arrhythmias, which validate our machine learning approach. 9
Results

63
Systematic in vitro pharmacology of marketed and withdrawn drugs 64
To link gene targets to ADR occurrence, we utilized in vitro pharmacology assay data for 2134 65 marketed or withdrawn drugs, generated by Novartis, and ADR reports from FAERS ( Figure 1A , 66 Supplementary Table 1 ). Withdrawn drugs and their assay data are also included due to the fact 67 that they are associated with a plethora of ADRs, and thereby constitute an important resource 68 for our predictive approach. Figure 1B summarizes the top 50% of frequently occurring primary 69 indications, classified by the Anatomical Therapeutic Chemical (ATC) codes, of the 2134 drugs 70 using a word cloud. The categories that have the highest number of compounds are 71 antibacterial, ophthalmological, and antineoplastic drugs. The in vitro pharmacology assay data 72 includes AC50 values for each drug at up to 218 different assays for 184 gene targets (see 73
Supplementary Table 2 for a list of target assays). There are 6 classes of these 184 gene 74 targets, with the majority (47%) of targets falling into G protein-coupled receptors (GPCRs) 75 ( Figure 1C) . Figure 1D is a heatmap visualization of the in vitro pharmacology assay data, 76
where each row is a drug, grouped by their ATC anatomical main group terms 18 , and each 77 column is a target assay, grouped by target class. It consists of AC50 values of drugs for target 78 assays. The heatmap is not a complete data matrix; 70% of drug-assay combinations have not 79 been tested, i.e. these combinations have NA value for AC50. Nevertheless, our data indicate 80 relatively uniform assaying with respect to the different drug classes.
Analysis of adverse event reports from FAERS connects drugs with human ADRs 82
We queried FAERS 15 using openFDA 19 for 2134 marketed or withdrawn drugs in November 83 2018 (FAERS Q4_2018 version) and retrieved 671143 adverse event reports (AERs) using our 84 data extraction criteria (Figure 2A ). We only included reports which were submitted by 85 physicians and were annotated as the primary suspect drug 20 . There are 464 drugs that did not 86 have a matching name in FAERS, 341 drugs that did not have any adverse event reports, and 87 1329 drugs with at least 1 adverse event report. We developed a significance test based on a 88 binomial null distribution and false discovery rate (FDR) multiple testing correction to determine 89 if the observed ADR occurrence was significantly high to be classified as an association (or 90 alternatively no association) between ADR and drug (see Methods for detail). Overall, we 91 observe a positive trend between the number of adverse event reports and the number of ADR 92 associations ( Figure 2B ). Antineoplastic and immunomodulatory drugs ( Figure 2B , blue, N=155) 93 have many ADR associations while the extent of ADR association for antihypertensive drugs 94 ( Figure 2B , red, N=35) varies more widely. As an example, we visualized our drug-ADR 95 associations ( Figure 2C ), in which ADRs are grouped by MedDRA System Organ Class (SOC) 96 level terms and drugs are grouped by ATC anatomical main group terms 18 , revealing that ADRs 97 are widespread across organs caused by antineoplastic and immunomodulating agents ( Figure  98 2C, label L), as well as nervous system drugs ( Figure 2C , label N). 99 100
Random forest model learns relationship between in vitro pharmacology and reported 101
ADRs in humans 102
We developed a machine learning approach to predict ADRs for a given drug from their in vitro 103 secondary pharmacology profiles ( Figure 3A) . We consider this a multi-label classification 104 problem because a given drug can cause multiple ADRs based on its possible engagement with 105 multiple targets and because a single target may be associated with multiple ADRs. We 106 discretized and one-hot encoded our in vitro pharmacology assay data (AC50 values) into 3 107 classes: highly active (AC50 < 3 μM), active (3 μM ≤ AC50 ≤ 30 μM) and inactive (AC50 > 30 μM). 108 Furthermore, we used the binarized drug-ADR associations as described above. We 109 constructed a random forest binary classifier for each ADR under the assumption that ADRs are 110 independent from each other. 413 features were used to predict 321 High Level Group Term 111 (HLGT) ADRs and 21 System Organ Class (SOC) ADRs. The unifying random forest model 112 (binary relevance model), which consists of 321 random forest ADR models, was first trained 113 using 5 fold cross validation where each fold is selected sequentially. We used 1329 drugs for 114 model construction because these drugs are associated with at least 1 recorded ADR in 115 FAERS. The remaining 805 drugs were not used for training or cross-validation. The model 116 predictions are in probability format, which is used later for target-ADR predictions, and in 117 boolean format ( Figure 3A) , to enable assessment of model performance via accuracy, macro-118 precision, macro-recall and Matthew's correlation coefficient (MCC), a performance measure 119 that takes class imbalance into account ( Figure 3B ). The unifying random forest model 120 performance of SOC ADRs and HLGT ADRs using the full training set (1329 drugs) and the 5 121 fold cross validation sets (266 drugs, averaged) are depicted in Figure 3B . Accuracy ranges 122 from 0.81 to 0.94, macro-precision ranges from 0.39 to 0.98, macro-recall ranges from 0.22 to 123 0.63, and MCC ranges from 0.37 to 0.82. Compared to SOC level (21 ADR terms), the finer 124 grain HLGT level (321 ADR terms) had fewer positive drug-ADR associations; additionally, the 125 performance of the HLGT and SOC models are comparable. We therefore proceeded with the 126 HLGT level models for further investigation. 127
For 55 of the 321 HLGT ADRs, the corresponding random forest models simply predicted zero 128 for all drugs as mostly none (and at most 4) of the 1329 drugs with adverse event reports were 129 associated with those ADRs (Supplemental Table 3 ). Since these models were not predictive, 130 we did not consider them for further analyses. For the remaining 266 ADRs, we could determine 131 performance metrics ( Fig 3C) . Accuracy and precision were high, ranging between 0.9 and 1, 132 whilst the recall and MCC range more widely ( Fig 3C) . This variability occurs for ADRs that have 133 only a few drugs associated with them ( Fig 3D) . As the number of associated drugs increases 134 and as `more positive training data accumulates, the models learn to better distinguish true 135 positives from false negatives so that their recall and MCC values increase ( Fig 3D) . 136 137
Random forest model predicts expected ADR profiles for anti-hypertensive drugs 138
As one demonstration of model validation, we analyzed the ADR profiles of 6 subclasses of 139 antihypertensive drugs: adrenergic alpha, adrenergic beta, ACE inhibitors, angiotensin AT2 140 inhibitors, calcium channel blockers and diuretics (Supplementary Table 4 ). The signature of the 141 anti-hypertensive drug subclass represents a set of ADRs that were common to all drugs in this 142 subclass. Each antihypertensive drug subclass has a unique ADR fingerprint in the FAERS 143 database which was closely predicted by our random forest model ( Figure 3E ). The accuracy 144 ranged from 0.984 to 1, with perfect specificity and precision (Supplementary Table 5 ). The 145 sensitivity ranged from 0.882 to 1, except for the diuretics sub-class, which had a sensitivity of the rest of the anti-hypertensive drugs do. Of note, the adrenergic alpha and adrenergic beta 148 receptor subclasses maintain distinct profiles in the predicted data. Specifically, the model 149 correctly predicts that adrenergic alpha receptor drugs are associated with suicidal and self 150 injurious behaviors, which has been reported in the literature 21, 22 . 151 152 Random forest model is able to capture ADRs for a test set of drugs 153
We utilized our random forest model to predict ADRs for 805 drugs that were not used for model 154 construction as they did not have any available ADRs in the FAERS Q4_2018 version, either 155 because there was no match with the drug name or there was no ADR report for that drug 156 submitted to FAERS. We re-queried FAERS for these 805 drugs in the beginning of 2019 157 (FAERS Q1_2019 version), and retrieved ADRs for 51 of them. These were used as an 158 independent test set to compare their ADR predictions with the actual ADR reports in FAERS 159 Q1_2019. 51 drugs had at least one ADR association in the later version ( Supplementary Table  160 6), and for 18 of them the model made at least one True Positive prediction (TP > 0). The 161 model performance metrics for these 18 drugs range from 0.77 to 0.99 for accuracy, from 0.1 to 162 0.57 for MCC, from 0.07 to 1 for precision, and from 0.01 to 1 for recall ( Figure 3F ). The model 163 is able to capture ADRs reported in the latest version of FAERS (Q1_2019) as well as ADRs 164 that are not reported in FAERS database yet but are reported elsewhere. For instance, 165 Glibenclamide (Glyburide), used for treating type 2 diabetes, has 3 TP hits, i.e. the model 166 correctly predicts these 3 ADRs that are reported in the latest version of FAERS. The model 167 suggests 3 more ADR association (FP = 3) with Glibenclamide: (1) epidermal and dermal 168 conditions; (2) gastrointestinal signs and symptoms; (3) respiratory disorders. These ADRs are 169 supported by the Drugs.com database 23 , even though they are not reported in the FAERS 170 database. These effects include hives, itching, skin rash, abdominal pain, nausea, shortness of 171 breath and wheezing. Another example, Arformoterol (Aformoterol), is a bronchodilator for 172 chronic obstructive pulmonary disease (COPD) treatment. Our model is able to capture 4 173 reported ADRs and 3 unreported ADRs including cardiac arrhythmias. According to a safety and 174 efficacy study on Arformoterol, some patients experienced cardiac arrhythmia-related adverse 175 events 25 . Overall, our random forest model proves to be a powerful tool to predict drug-ADR 176 associations from in vitro pharmacological drug profiles. 177
We used the trained ADR models to predict which target genes are associated with ADRs. To 180 achieve this, we utilized the Gini importance score to rank features for their importance in 181 random forest model performance ( Figure 4A ). For a given ADR, we selected assays that had 182 multiple AC50 features represented in the top 5% of Gini scores ranking (see Methods for detail). 183
We then generated ADR probability predictions for an in silico compound that is assumed to 184 target only the selected assay with an AC50 value corresponding to a represented feature. We 185 also assumed no available data for all other assays. Using this in silico AC50 profile as an input 186 to the ADR model, we could generate the ADR probability. By assessing differences in ADR 187 probabilities (two sample t-test, FDR corrected p-value < 0.1) between different AC50 classes, 188 e.g. 0-3 μM vs inactive, we predict positive or negative correlations, collectively termed 189 associations, between the selected target assay and ADR. Unsurprisingly, some ADRs did not 190 generate any target associations. 191
To find biologically meaningful associations, we first filtered out HLGT terms belonging to SOC 192 classes that are not specific to human body parts or only procedural or intervention related (see 193
Methods for detail). Secondly, we filtered out terms that fall under the SOC class neoplasms, 194 since genes are often severely misregulated in cancers and therefore not representative of 195 neoplasm-related ADRs in the organ where the tumor resides. After filtering, we found 221 196 statistically significant target-ADR associations ( Figure 4B , full details including p-values in 197 Supplementary Table 7 ). 51 out of 184 target assays and 132 out of 321 ADRs are represented 198 ( Figure 4B ). 199
To gain confidence in our ADR-target identification procedure, we focused on the GABAA 200 receptor, the primary target of benzodiazepines (BZD), a drug class known to be psychoactive. 201 Consistently, our model predicts that this ligand-gated chloride ion channel assay is associated 202 with 14 ADRs, 13 of which are neurologically and psychiatrically related, including disturbances 203 in thinking and perception, sleep disorders, depression and suicidal behaviors ( Figure 4B , 204 Supplementary Table 7) . 205 206
Evidence for targets that are predicted to cause cardiovascular-related ADRs 207
To further validate our model's ability to predict target-ADR associations, we investigated a 208 group of cardiovascular ADRs. We found that hERG binding was associated with cardiac 209 arrhythmias and heart failure at the HLGT level. hERG encodes for a subunit of the cardiac 210 potassium ion channel and contributes to cardiac electrical activity, which is necessary to 211 regulate the heartbeat. The mechanism of action for drug-induced arrhythmias by blocking 212 hERG has been described in numerous human 26 and animal studies 27 , as well as structural 213 modeling 28 studies ( Table 1 ). We did not find an ADR probability associated with 0-3 μM AC50 214 of hERG binding, likely because such strong binding to hERG is a common reason for 215 deprioritizing drug candidates in development 29 . 216
The model predictions also suggest that PDE3 inhibition is associated with cardiac valve 217 disorders ( Table 1 ). PDE3 inhibition is used clinically to treat dilated cardiomyopathy 30 , which 218 encapsulates valvular heart disorder. However, the PDE3 therapeutic window is narrow, 219 partially due to complex signaling networks 31 , and careful dosing is required to avoid increased 220 mortality in response to treatment. 221
Our model also predicts that adenosine transporter (AdT) inhibition increases the risk of 222 pericardial disorders (Table 1) . For this scenario, we did not find supporting evidence in the 223 literature. The data also suggest that glucocorticoid receptor (GR) binding is more likely to lead 224 to myocardial disorders if the drug has high affinity for GR. This is supported by the finding that 225 glucocorticoid treatment of patients with rheumatoid arthritis increased the risk of myocardial 226 infarction 32 . Furthermore, it is known that dysregulation of glucocorticoids can give rise to 227 cardiotoxicity 33 . 228
Taken together, this investigation of genes associated with cardiovascular ADRs confirms the 229 well-known association of hERG with cardiac arrhythmia, and also highlights ADR associations 230 that would merit further experimental investigation. 231 232
Evidence for predicted associations of COX-2, PDE3 and hERG with kidney related ADRs 233
Another important class of ADRs are related to the kidney ( Figure 4B , label: renal). We found 234 COX-2 associated with nephropathies (Table 2) , which has been well recognized and evidenced 235 previously [34] [35] [36] . Interestingly, another model prediction is PDE3 sensitivity correlating with 236 congenital renal and urinary tract disorders (Table 2) . According to a mouse model study 37 , 237 PDE3 inhibition could be a contributing factor in Polycystic Kidney Disease (PKD), as PDE3 238 protein levels are already lower in PKD than WT kidneys. Lastly, we found an unexpected 239 association between hERG and renal disorders (excluding nephropathy) ( Table 2) . One study 240 has found a loss of hERG function in renal cell carcinoma 38 . In humans, hERG expression in 241 the kidney is much lower than in the heart 39 . Therefore, we conclude that a link between hERG 242 and renal disorders remains a prediction that warrants further investigation. 243
PDE3 and nuclear hormone receptors AR, ERa and PR are overrepresented in ADR 245 associations 246
To investigate if the number of different drugs tested for a target assay is predictive to the 247 number of ADRs associated with that target ( Figure 4C ), we calculated their Pearson correlation 248 coefficient to be moderate (r=0.4). However, some targets had considerably more associated 249
ADRs than other targets that were tested a similar number of times, indicating that more 250 frequently performed assays do not necessarily result in a higher number of associated ADRs 251 ( Figure 4C ). Out of all target assays, PDE3 was associated with the most ADRs (40) ( Figure  252 4C), falling in a wide range of SOC classes ( Figure 4B , Supplementary Table 7 ). Furthermore, 253 nuclear hormone receptors for androgen (AR), estrogen (ERa) and progesterone (PR) binding 254 assays also have disproportionately many ADR associations, compared to their frequency of 255 testing ( Figure 4C ). As expected, AR (7/14 ADRs), ERa (9/10 ADRs) but not PR (0/17 ADRs) 256 are associated with sexual reproductive organ and pregnancy-related ADRs ( Figure 4B , 257 Supplementary Table 7 ). Androgen is produced in the adrenal gland 40 and we predict a link 258 between AR with adrenal gland disorders, with evidence in mouse studies 41 . Interestingly, the 259 model predicted 6 ocular ADRs associated to PR, including vision disorders, anterior eye 260 structural change (deposit and degeneration), infections, irritations and inflammations and 261 structural changes ( Figure 4B , Supplementary Table 7) , for which we could find supporting 262 evidence 42 . 263 264 Bile salt export pump BSEP associations with ADRs in various organs 265 BSEP, encoded by ABCB11 and a member of the superfamily of ATP-binding cassette (ABC) 266 transporters, is most highly expressed in the liver 39 . Drugs that target BSEP are often 267 associated with hepatotoxicity 43 . However, initially, we did not find a BSEP association with 268 hepatic and hepatobiliary disorders. To investigate this false negative prediction, we noted that 269 the dynamic range of the BSEP assay specifically extends up to 300 μM because the liver is 270 likely to experience a higher concentration of orally delivered drugs than the general circulation 271 44 . As a result, most of our data falls into the 'inactive' (>30 μM) class. Consistently, the BSEP 272 inactive feature had the highest Gini score for this HLGT term, while its two active features had 273 much lower Gini scores, falling outside of the top 5%. To take the extended dynamic range into 274 account, we altered the BSEP assay class boundaries to 0-30 μM, 30-300 μM and >300 μM and 275 retrained the random forest model. In this case, we did find BSEP associated with hepatic and 276 hepatobiliary disorders (Table 3) , according to our association criteria ( Figure 4A ). We repeated 277 this procedure whilst replacing the first class boundary (30 μM) with 100 μM and found the 278 same association again, indicating the robustness of our results. Interestingly, with our original 279 AC50 discretizations ( Figure 1D ), we found BSEP associated with 7 other ADRs from various 280 organ classes (Table 3) , much more than other targets that were assayed at a similar frequency 281 ( Figure 4C ). This suggests that compounds potent against BSEP (AC50 < 30 μM) could cause 282 adverse effects in addition to hepatotoxicity, which already occurs at lower potency. We found 283 BSEP associated with urolithiasis and with disorders of the thyroid gland, upper respiratory tract 284 disorders (excl infections), lipid metabolism and central nervous system (Table 3 ). Since BSEP 285 expression is much lower in these organs 39 , we searched the literature for evidence including a 286 substrate of BSEP, bile acid. We could find previous studies linking bile acid to these disorders 287 (Table 3) , which suggests an indirect relation between BSEP and these ADRs through bile acid 288 metabolism. Lastly, we found BSEP associated with foetal complications and pregnancy 289 conditions (Table 3) In this study we have taken a machine learning approach to predict human ADRs from the in 294 vitro secondary pharmacology profiles of a large number of marketed and withdrawn drugs. 295
Several prior studies focus on predicting ADRs directly from chemical drug structure 47,48 . 296 However, utilizing functional information such as in vitro pharmacological targeting of common 297 (off) targets represents a viable alternative to bridge the complex relationship between drugs 298 and their effects in the human body 4 . 299 300 Our random forest model performance metrics are good considering the sparse coverage (2134 301 drugs) over a large input space (3 184 possibilities) and partial overlap with ADR reporting for 302 these drugs, making ADR occurrence prediction effectively a one shot learning task. 303 Importantly, optimizing test performance was not the main objective of this study. Instead, we 304 endeavored to find biologically meaningful target-ADR associations. To achieve this without 305 relying on test performance, we trained on all data and made use of Gini scores to robustly 306 select relevant features for ADR probability predictions. Our novel method for target-ADR 307 associations was able to recapitulate well recognized causal relations, such as hERG with 308 cardiac arrhythmias. For others, we were able to find literature evidence in animal or in vitro 309 studies but our study is, to our knowledge, a first in human report. Another fraction of target-310 ADR associations represents predictions of novel, unexpected or little known associations, such 311 as Adenosine Transporter (AdT) and pericardial disorders, for which we could find little evidence 312 other than our analysis of adverse event reports. Overall, our 221 associations form a rich 313 resource that can be used for further mechanistic studies in the drug discovery process. 314 315 Our random forest model is agnostic to molecular mechanisms; therefore, resulting associations 316 could arise from indirect regulation. A likely example is the bile transporter BSEP, which is 317 associated with numerous ADRs, although it is most highly expressed in the liver and kidney. 318
We have related our findings to evidence that misregulation of its substrate, bile acid, could 319 result in disorders related to kidney stones, lipid metabolism, thyroid gland, respiratory system 320 and central nervous system. This also indicates the strength of our approach, which can relate 321 genes to physiological processes unbiasedly in humans, without any interventions or large scale 322 genome-wide association studies, but solely with voluntary adverse event reporting. 323 324 While we recommend this approach to find target-ADR associations to impact safety awareness 325 in drug discovery, we are also aware of the limitations. Firstly, the presented analyses are 326 limited by the input data. The in vitro data matrix is incomplete (targets in the in vitro 327 pharmacology panel cover a small fraction of the biological target space and not all drugs were 328 tested in all assays). We recognize that the present set of targets is biased towards the GPCR 329 target family with limited representation of other therapeutic or ADR-associated targets such as 330 ion channels and kinases. Also, data are influenced by prior knowledge; for example, more than 331 87% of all drugs in the set were tested for hERG activity. High affinity (lower AC50 value) for 332 hERG is associated with higher probability for QT prolongation for human and non-human 333 preclinical species 26, 27 . As discussed earlier, there are not many drugs with a hERG AC50 value 334 in the highly active class (0-3 μM), which is a commonly encountered roadblock for drug 335 candidates to progress towards clinical trials 29 . Only about 10% of all drugs fall into the highly 336 active class in our assay data. To limit feature engineering, our AC50 discretization into three 337 classes ( Figure 1D ) was kept uniform across all assays. Notably for the BSEP assay, the 338 dynamic range extends up to 300 μM and as a result most of our data falls into the 'inactive' 339 (>30 μM) class. Consequently, we did not find the expected association with hepatotoxicity. We rectified this by reclassifying the BSEP assay data according to levels required for hepatotoxicity 341 of BSEP inhibition 49,50 and indeed recovered the expected association. 342
Secondly, in vitro potency is a very simplified marker of clinical effect, and does not take into 343 account prolonged dosing, comorbidity or pharmacokinetic/pharmacodynamic relationships (e.g. 344 therapeutic window). For some targets, although very rarely, non-human proteins were assayed 345 (e.g. rat brain was used as a source for the benzodiazepine receptor) which may not be a direct If a drug was not tested against a specific assay, the AC50 value was set to NA (not available). 386 AC50 values from similar assays with the same gene target were merged to reduce the NA data 387 and features in the random forest model; this procedure resulted in 184 different target assays 388 (Supplementary Table 2 ). In case any merged assays had multiple AC50 values for the same 389 drug, we averaged these geometrically to take into account variation over orders of magnitudes. In this study, we utilized openFDA to acquire FAERS reports related to the query compounds 396 15, 19 . This Elasticsearch-based API provides a raw download access to a large volume of 397 structured datasets, including adverse events reports from FAERS. 398
399
We used generic compound names (e.g. "Amoxicillin") to query through the openFDA interface, 400 accessed programmatically using Python. In order to maximize the coverage over FDA 401 datasets, we normalized generic names to uppercase format followed by a name similarity 402 metric to filter out unrelated records in our analysis. We included reports when the Jaro 403 similarity between the query generic name and reported compound name was equal or greater 404 than 0.8. 405
As the FAERS database contains information voluntarily submitted by healthcare professionals, 407 consumers, lawyers and manufacturers, adverse event reports may be duplicated by multiple 408 parties per event, and may be more likely to contain incorrect information if submitted by a non-409 medical professional. To reduce reporting bias and increase report information accuracy, we 410 only analyzed reports submitted by physicians (data field: 'qualification' = 1). In this subset of 411 adverse event reports, the data were further filtered by reported drug characterization, which 412 indicates how the physician characterized the role of the drug in the patient's adverse event. A 413 drug can be characterized as a primary suspect drug, holding a primary role in the cause of the 414 adverse event (data field: 'drugcharacterization' = 1); a concomitant drug ('drugcharacterization' 415 = 2); or an interacting drug ('drugcharacterization' = 3). Here, we included only primary suspect 416 drug reports. Without this restriction, model performances did not improve. We obtained all 417 adverse events reports corresponding to the query compound that passed through the 418 aforementioned filters. 419 420 Adverse event report descriptions are coded as medical terms of MedDRA terminology 17 . 421
Medical observations can be reported using 5 hierarchical levels of medical terminology, 422 ranging from a very general System Organ Class term (e.g. gastrointestinal disorders) to a very 423 specific Lowest Level Term (e.g. feeling queasy). Each term is linked to only one term on a 424 higher level. For each report, we recorded all MedDRA Reaction terms (data field: 425 "reactionmeddrapt") at the Preferred Term level and mapped these Preferred Terms to Higher 426
Level Group Term and System Organ Class level. For each (ADR term, drug) tuple, we then 427 calculated the ADR occurrence, defined as the following fraction: number of adverse event 428 reports containing that ADR term relative to the total number of ADR reports for that drug. 429 430
Random forest models 431
To construct and train our models ( Figure 3A) , we used AC50 values for a panel of target assays 432 for marketed drugs (model input; independent variable) and ADR occurrences of the 433 compounds (model output/predictions; dependent variable). Since there may be several ADRs 434 associated with any given drug, we considered this a multi-label learning problem 52 . We took a 435 "first-order strategy", i.e. we assume there is no correlation between different ADRs, and a 436 "divide and conquer" strategy, i.e. we decompose our multi-label learning task into n 437 independent binary classification problems, where n is the number of different ADR terms in our 438 output data (n = 26 for SOC and n = 321 for HLGT level respectively). We built a random forest 439 53 binary classifier for each ADR using Binary Relevance with the random forest modeling option 440 in mldr package 54 and utiml package in R 55 . 441
442
To define the features for the random forest models, we discretized and one-hot encoded our 443 input AC50 values. We defined 3 classes (levels) of AC50 ranges for each target assay. 444 The observed ADR occurrences were discretized into binary dependent variables. To achieve 453 this, first let Nd be the total number of ADR reports for a given drug. The probability to observe 454 an ADR occurrence O ADR = X / Nd at random is equivalent to choosing that ADR X times out of 455
Nd with X distributed binomially: X~bin(Nd, p=1/n). Here, n represents the total number of ADRs 456 as defined above. Under this null distribution, we calculate the p-values for all observed ADR 457 occurrences O ADR for a given drug, and then perform a Benjamini-Hochberg False Discovery 458 Rate (FDR) correction (using the Python statsmodels package). If an FDR-corrected p-value is 459 < 0.01, then the ADR value for that drug is 1, reflecting an association; 0 otherwise. 460 461 All random forest models were first trained using 5 fold cross validation and each fold is 462 selected sequentially. 1063 drugs were used for training and 266 drugs were used for testing in 463 each fold. Then, the drugs with at least 1 ADR report are used as a training set. For a given 464 (drug) input of AC50 values and ADR, the random forest model output, termed ADR probability, 465 can be interpreted as the probability that the ADR is associated with the drug. To enable direct 466 comparison of model predictions with binarized ADR occurrences, we binarized these ADR 467 probabilities with a simple threshold value of 0.5. These binary values were used for training, 468 cross validation and to calculate classification performance metrics ( Figure 3B 
Determination of target-ADR associations 481
To find associations between gene target assays and ADRs (Figure 4) , we first generated ADR 482 probabilities specific to a given assay. As a model input, one out of its three random forest input 483 features' value was set to 1 and all others to 0. This simulates the scenario of an in silico 484 compound that is potent with an AC50 value in the range corresponding to the positive feature 485 only. We then utilized the ADR's random forest model, pre-trained on all available marketed 486 drug data (see previous section), to calculate the resulting ADR probability. We repeated this 487 procedure for each feature of all assays and each ADR. 488 489 To select the predictive features for a given ADR, we ordered the pre-trained random forest 490 model's input features according to their Gini importance score 56 and denote the top 5% as 491 significant features. Our criteria for a gene (target assay) -ADR pair were: 492
• For a given ADR: at least 2 out of 3 assay features need to be significant in order to 493 make a reliable comparison between the ADR probabilities with respect to AC50 values. 494
• At least one of the ADR probabilities of the significant features has to be larger than 495 zero. 496
497
We filtered out target-ADR pairs if the ADR term maps to the following SOC classes, which are 498 not specific to body parts or underlying human biology: 499
• general disorders and administration site conditions 500
• injury, poisoning and procedural complications 501 To ensure the reproducibility of the target-ADR pair selection procedure, we repeated the 507 random forest model training with different seeds for a total of 5 times. We then took the union 508 of the 5 sets of target-ADR pairs and discarded pairs that were only found once out of 5 runs. 509
Finally, to determine if the mean ADR probabilities between the selected AC50 classes were 510 statistically significantly different, we performed a two-sample t-test with sample sizes equal to 511 the number of times a class was selected (ranging from 2 to 5 times) using the Python 512 scikit.stats package. In case all three AC50 classes were represented, we tested the highly 513 active versus inactive class. We then performed a Benjamini-Hochberg FDR correction. If the 514 FDR-corrected p-value is < 0.1, then the target-ADR pair is considered a statistically significant 515 association ( Figure 4B , Supplementary Table 7) . 516
517
To evaluate the relation between the HLGT level ADR term hepatic and hepatobiliary disorders 518 and target assay BSEP, we also trained and analyzed two random forest models as described 519 above to find target-ADR pairs but with only the BSEP assay data discretized with class Table 1 Predicted associations between targets and cardiac ADRs. 613
High Level Group Terms (HLGT; MedDRA) associations with targets and Adverse Drug 614 Reaction (ADR) probability in three concentration ranges (third column). Evidence of the ADR-615 target pairs were obtained from peer reviewed publications (fourth column). hERG: human 616
Ether-a-go-go-Related Gene associated potassium channel; PDE3: phosphodiesterase-3 617 enzyme; GR: glucocorticoid receptor; AdT: Adenosine transporter; COX-2: cyclooxygenase 618 enzyme, type 2. 619 Table 3 Predicted ADR associations with inhibition of the Bile Salt Export Pump (BSEP) 628 transporter (detailed legend in Table 1) 
